Subclinical Hypothyroidism: Should You Be Treated or Just Watched?

Thyroid Health · 5 min read

It happens in clinics every week. A routine blood test comes back, TSH is slightly elevated — say 6 or 7 — T3 and T4 are perfectly normal. An alarming-sounding report is handed over, a prescription for levothyroxine often follows, and the patient leaves convinced something is seriously wrong with their thyroid.

Sometimes that is correct. Often, it is not.

What subclinical hypothyroidism actually is

The thyroid produces T3 and T4 — hormones that regulate metabolism, energy, mood, and body temperature. TSH, made by the pituitary gland, signals the thyroid to produce more. When thyroid hormones are adequate, TSH stays low. When they dip even slightly, TSH rises to compensate.

In overt hypothyroidism, TSH is high and T4 is low — the thyroid is genuinely underperforming and treatment is necessary. In subclinical hypothyroidism, TSH is elevated but T4 and T3 remain normal. The pituitary is working harder than usual, but the actual thyroid hormone output is still sufficient. This is a fundamentally different situation — and treating it as though it were overt hypothyroidism is where most of the confusion begins.

How common is it, and who gets it

Subclinical hypothyroidism affects roughly 3 to 15 percent of the general population. In India, women are affected at nearly double the rate of men — 11.4 percent versus 6.2 percent in population-based data. Prevalence rises with age, and the condition is more common in those with a family history of thyroid disease and in those with elevated anti-TPO antibodies, a marker of autoimmune thyroid activity. That last point is one of the most important factors in deciding how to respond.

The number that changes everything: TSH 10

Guidelines from the American Thyroid Association, the European Thyroid Association, and the 2023 Korean Thyroid Association broadly agree: a TSH below 10 mIU/L with normal T4 in an otherwise healthy adult does not automatically require treatment. Above 10, the evidence for levothyroxine is stronger — particularly in younger patients and those with cardiovascular risk factors or symptoms.

A TSH of 6 and a TSH of 12 are both "elevated." They sit in very different clinical territories.

The case for watchful waiting

For a person with TSH between 4.5 and 10, normal T4, no symptoms, and no anti-TPO antibodies, the evidence for immediate treatment is weak — for three reasons.

First, TSH fluctuates. Illness, stress, poor sleep, even the time of day can shift it. A single mildly elevated result is not a diagnosis. Guidelines recommend repeating the test two to three months later before acting. In many cases, it returns to normal on its own.

Second, subclinical hypothyroidism often resolves without treatment. Studies show that 30 to 50 percent of cases either normalise spontaneously or remain stable for years without progressing to overt hypothyroidism.

Third, overtreatment carries real risks. Excessive levothyroxine can drive TSH too low, which is associated with atrial fibrillation, accelerated bone loss in postmenopausal women, and cardiovascular stress. A patient treated unnecessarily can end up with a genuinely induced problem. The TRUST trial — a rigorous placebo-controlled study of levothyroxine in older adults with subclinical hypothyroidism — found no meaningful improvement in symptoms or quality of life compared to placebo. The fatigue, weight gain, and low mood most commonly attributed to a slightly elevated TSH were not improved by treatment in those without overt hormone deficiency.

When treatment does make sense

Pregnancy or planning to conceive is the clearest case. Thyroid hormone is critical for foetal brain development, especially in the first trimester. Treatment thresholds are lower in this context, and thyroid function should be assessed early in any pregnancy.

Strongly positive anti-TPO antibodies alongside elevated TSH indicate Hashimoto's thyroiditis. In the Indian context this is particularly relevant — Indian patients progress from subclinical to overt hypothyroidism at higher rates than Western populations, making antibody status a meaningful guide to how closely to monitor and when to treat.

TSH above 10 shifts the evidence toward treatment regardless of symptoms.

Genuine symptoms — specific, notable changes in energy, weight, cognition, or temperature regulation that are meaningfully affecting daily life — warrant a clinical assessment of whether a trial of levothyroxine is worth pursuing.

Cardiovascular risk also matters. Some evidence links mild subclinical hypothyroidism with unfavourable lipid profiles, and the 2023 Korean guidelines note that treatment may be appropriate where subclinical hypothyroidism coexists with dyslipidaemia or underlying coronary artery disease.

The Indian context

Levothyroxine is among the most prescribed medications in India, and subclinical hypothyroidism is frequently treated here at TSH thresholds that the evidence does not support. Some of this reflects a legitimate concern — Indian patients do show higher rates of progression to overt hypothyroidism, and anti-TPO positivity is common. But it also reflects a pattern where a mildly elevated TSH on a routine panel leads directly to a prescription without the clinical conversation it deserves.

The TSH is a signal. What it signals — and what to do about it — depends on the T4, the antibodies, the symptoms, the age, the reproductive status, and the trend over time.

What to do if you have this result

Repeat the test in two to three months before any decision is made. Ask for anti-TPO antibodies alongside TSH and T4 — this single addition changes the interpretation significantly. Be specific about symptoms, not a vague list but genuine, notable changes. If you are a woman of reproductive age, mention whether pregnancy is planned. And if levothyroxine is recommended for a TSH of 5 or 6 with no symptoms and no special circumstances, it is entirely reasonable to ask whether monitoring first is an option.

A mildly elevated TSH is not, on its own, a diagnosis. What it means depends on the full picture — and that is a conversation worth having carefully.

If you have a thyroid report you are unsure about, a clinical review that looks at your complete picture — not just the TSH number — is the most useful step you can take.